Big news out of New Jersey this morning as a biotech company said it received “positive feedback” from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC, according to a release.
Traders were in a rush to grab up shares of Tharimmune Inc. (Nasdaq:THAR) following the news, with shares of this micro cap currently trading around $4.08/share (+100.99%) at the time of writing. This move was a strong breakout of a multi-month downtrend that this stock has been stuck in, which could be an indication of things to come. Keep your eye on this one!
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology and inflammation. The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers.
Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
View the original article on AllPennyStocks.com
]]>